Carlos A Castaneda, Miluska Castillo, Joselyn Sanchez, Luis Bernabe, Katherin Tello, Nancy Suarez, Raul Alatrista, Ximena Quiroz-Gil, Alexandra Granda-Oblitas, Javier Enciso, Nathaly Enciso, Henry L Gomez
{"title":"与乳腺癌中 CD44 和 CD63 表达相关的临床病理特征","authors":"Carlos A Castaneda, Miluska Castillo, Joselyn Sanchez, Luis Bernabe, Katherin Tello, Nancy Suarez, Raul Alatrista, Ximena Quiroz-Gil, Alexandra Granda-Oblitas, Javier Enciso, Nathaly Enciso, Henry L Gomez","doi":"10.3332/ecancer.2024.1779","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>CD44 is a cell-surface transmembrane glycoprotein that participates in the regulation of many cellular processes, including cell division, adhesion, migration and stem-like characteristics. CD63 is involved in the exocytosis process.</p><p><strong>Objective: </strong>To evaluate the relationship between CD44 and CD63 expression and clinicopathological features, including tumor-infiltrating lymphocytes (TILs), phosphoinositide 3-kinase (PIK3CA) mutation and survival.</p><p><strong>Methodology: </strong>CD44 and CD63 were stained in samples from 101 breast cancer cases from Peruvian women.</p><p><strong>Results: </strong>Median age was 52 years, most were most were grade-3 (68%), estrogen receptor (ER)+ (64%) and stage II-III (92%). Median ki67 was 30%, median stromal TIL was 30% and <i>PIK3CA</i> mutation was found in 49%. Longer survival was associated with earlier stages (<i>p</i> = 0.016), lower ki67 (<i>p</i> = 0.023), ER+ (<i>p</i> = 0.034), luminal phenotype (<i>p</i> = 0.029) and recurrence (<i>p</i> < 0.001). CD44 was classified as high cell density staining in 57% and high intensity in 55%. High CD44 density was associated with younger age (<i>p</i> = 0.043), triple-negative phenotype (<i>p</i> = 0.035) and shorter survival (<i>p</i> = 0.005). High CD44 expression was associated with short survival (<i>p</i> = 0.005). High CD63 cell density was found in 56% of cases and was associated with ER-positive (<i>p</i> = 0.045), low TIL levels (<i>p</i> = 0.007), Luminal-A (<i>p</i> = 0.015) and low CD44 intensity (<i>p</i> = 0.032).</p><p><strong>Conclusion: </strong>CD44 expression was associated with aggressive features and low CD63 density staining.</p>","PeriodicalId":11460,"journal":{"name":"ecancermedicalscience","volume":"18 ","pages":"1779"},"PeriodicalIF":1.2000,"publicationDate":"2024-09-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11489100/pdf/","citationCount":"0","resultStr":"{\"title\":\"Clinicopathological features associated with CD44 and CD63 expression in breast cancer.\",\"authors\":\"Carlos A Castaneda, Miluska Castillo, Joselyn Sanchez, Luis Bernabe, Katherin Tello, Nancy Suarez, Raul Alatrista, Ximena Quiroz-Gil, Alexandra Granda-Oblitas, Javier Enciso, Nathaly Enciso, Henry L Gomez\",\"doi\":\"10.3332/ecancer.2024.1779\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Background: </strong>CD44 is a cell-surface transmembrane glycoprotein that participates in the regulation of many cellular processes, including cell division, adhesion, migration and stem-like characteristics. CD63 is involved in the exocytosis process.</p><p><strong>Objective: </strong>To evaluate the relationship between CD44 and CD63 expression and clinicopathological features, including tumor-infiltrating lymphocytes (TILs), phosphoinositide 3-kinase (PIK3CA) mutation and survival.</p><p><strong>Methodology: </strong>CD44 and CD63 were stained in samples from 101 breast cancer cases from Peruvian women.</p><p><strong>Results: </strong>Median age was 52 years, most were most were grade-3 (68%), estrogen receptor (ER)+ (64%) and stage II-III (92%). Median ki67 was 30%, median stromal TIL was 30% and <i>PIK3CA</i> mutation was found in 49%. Longer survival was associated with earlier stages (<i>p</i> = 0.016), lower ki67 (<i>p</i> = 0.023), ER+ (<i>p</i> = 0.034), luminal phenotype (<i>p</i> = 0.029) and recurrence (<i>p</i> < 0.001). CD44 was classified as high cell density staining in 57% and high intensity in 55%. High CD44 density was associated with younger age (<i>p</i> = 0.043), triple-negative phenotype (<i>p</i> = 0.035) and shorter survival (<i>p</i> = 0.005). High CD44 expression was associated with short survival (<i>p</i> = 0.005). High CD63 cell density was found in 56% of cases and was associated with ER-positive (<i>p</i> = 0.045), low TIL levels (<i>p</i> = 0.007), Luminal-A (<i>p</i> = 0.015) and low CD44 intensity (<i>p</i> = 0.032).</p><p><strong>Conclusion: </strong>CD44 expression was associated with aggressive features and low CD63 density staining.</p>\",\"PeriodicalId\":11460,\"journal\":{\"name\":\"ecancermedicalscience\",\"volume\":\"18 \",\"pages\":\"1779\"},\"PeriodicalIF\":1.2000,\"publicationDate\":\"2024-09-26\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11489100/pdf/\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"ecancermedicalscience\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.3332/ecancer.2024.1779\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"2024/1/1 0:00:00\",\"PubModel\":\"eCollection\",\"JCR\":\"Q4\",\"JCRName\":\"ONCOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"ecancermedicalscience","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.3332/ecancer.2024.1779","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2024/1/1 0:00:00","PubModel":"eCollection","JCR":"Q4","JCRName":"ONCOLOGY","Score":null,"Total":0}
Clinicopathological features associated with CD44 and CD63 expression in breast cancer.
Background: CD44 is a cell-surface transmembrane glycoprotein that participates in the regulation of many cellular processes, including cell division, adhesion, migration and stem-like characteristics. CD63 is involved in the exocytosis process.
Objective: To evaluate the relationship between CD44 and CD63 expression and clinicopathological features, including tumor-infiltrating lymphocytes (TILs), phosphoinositide 3-kinase (PIK3CA) mutation and survival.
Methodology: CD44 and CD63 were stained in samples from 101 breast cancer cases from Peruvian women.
Results: Median age was 52 years, most were most were grade-3 (68%), estrogen receptor (ER)+ (64%) and stage II-III (92%). Median ki67 was 30%, median stromal TIL was 30% and PIK3CA mutation was found in 49%. Longer survival was associated with earlier stages (p = 0.016), lower ki67 (p = 0.023), ER+ (p = 0.034), luminal phenotype (p = 0.029) and recurrence (p < 0.001). CD44 was classified as high cell density staining in 57% and high intensity in 55%. High CD44 density was associated with younger age (p = 0.043), triple-negative phenotype (p = 0.035) and shorter survival (p = 0.005). High CD44 expression was associated with short survival (p = 0.005). High CD63 cell density was found in 56% of cases and was associated with ER-positive (p = 0.045), low TIL levels (p = 0.007), Luminal-A (p = 0.015) and low CD44 intensity (p = 0.032).
Conclusion: CD44 expression was associated with aggressive features and low CD63 density staining.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
